Figure 1. Summary Genotype-Positive Patients Showed Higher Composite Adverse Event and Device-Related Rates. Kaplan-Meier analysis demonstrated shorter event-free survival in genotype-positive patients (P = 0.005; median 6.1 months vs 43.5 months). In multivariate Cox analysis, genotype positivity remained an independent predictor of adverse outcomes after adjustment for left ventricular ejection fraction (LVEF) and left ventricular end-diastolic diameter (LVEDD) (HR: 3.85; 95% CI: 1.61-9.19; P = 0.002). AF = atrial fibrillation; CAD = coronary artery disease; DCM = dilated cardiomyopathy; HF = heart failure; ICD = implantable cardioverter-defibrillator; LVAD = left ventricular assist device; NGS = next-generation sequencing; VHD = valvular heart disease.
We only have this paper's title and publication details.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: